cc-93269
mAbexperimentalMulti-specific
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Apr 3, 2018 (NCT03486067)
Timeline
Indications
Mechanism of action
TNFRSF17 adcc
- T-cell surface glycoprotein CD3 epsilon chainImmunity, passive
CD3E immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068570 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07219563 | Phase 1 | Dec 1, 2025 | Icahn School of Medicine at Mount Sinai |
| NCT06232707 | Phase 3 | May 3, 2024 | Bristol-Myers Squibb, Celgene |
| NCT06163898 | Phase 1/Phase 2 (Phase 2) | Jan 15, 2024 | Bristol-Myers Squibb, Celgene |
| NCT06121843 | Phase 1 | Dec 31, 2023 | Bristol-Myers Squibb |
| NCT03486067 | Phase 1 | Apr 3, 2018 | Celgene |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 3 | 1 | 3 | 2023 |
| Celgene | For profit | 3 | 3 | 3 | 2018 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 1 | 1 | 2025 |
3 organizations
Page 1 / 1